
Baxter (BAX) Stock Forecast & Price Target
Baxter (BAX) Analyst Ratings
Bulls say
Baxter International's stock outlook is supported by positive sales growth in its Healthcare Systems & Technologies segment, which reported increases of approximately 6% and 2% year-over-year in the first and second quarters of 2025, respectively. The company has strategically expanded its product offerings through the acquisition of Hillrom, which enhances its competitive positioning in the healthcare market by adding essential hospital equipment. Additionally, management indicated that pricing initiatives are expected to contribute a one-time sales growth benefit of about 100 basis points in 2024 and 2025, further strengthening the financial outlook for the company.
Bears say
Baxter International's financial performance in the second quarter of 2025 was marked by below-consensus results in sales, gross margins, and earnings per share, indicating ongoing challenges in operational efficiency. The company has faced a tumultuous period from 2021 to 2023, characterized by several operational missteps that have resulted in inconsistent quarterly performances and negative revisions to future guidance. Furthermore, the reported gross margins of 40.7% and operating margins of 15.1% both fell short of consensus estimates, reflecting significant sales softness and unfavorable manufacturing conditions.
This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.
Baxter (BAX) Analyst Forecast & Price Prediction
Start investing in Baxter (BAX)
Order type
Buy in
Order amount
Est. shares
0 shares